Advances in cancer therapy have led to improved objective outcomes such as survival, objective
responses to treatment, and toxicity. Recently, key goals during the treatment of cancer have been, not
only to achieve better survival times and responses,but also to produce an improvement in the patient’s
quality of life (QOL), and to maintain a good QOL during treatment. This is especially important for
patients with advanced cancer who have limited survival expectancies. Thus,evaluation of the QOL
has been included as one of the major endpoints in many recent phase III trials for patients with advanced
cancer